Heartflow

1.1 Identity and Business Model

Heartflow is a Delaware corporation formed in 2007 and a public medical-technology software company trading as HTFL. Its filings describe a usage-driven model: physicians order FFRCT Analysis, Plaque Analysis, or both, and Heartflow recognizes revenue when it delivers the requested analysis. The platform was commercialized in 2015, so this is an established workflow business rather than a pre-revenue AI developer. The latest annual filing still lists Mountain View as the principal executive-office location, while the Q1 2026 call disclosed a facilities impairment associated with relocating headquarters to San Francisco. The legal and operating address should therefore be confirmed rather than treating either city as an unqualified current headquarters statement.[CO001, CO002, CO003, CO004]

1.2 Operating Scale and Public-Company Transition

Heartflow reported $176.0 million of revenue for 2025 and $52.6 million for Q1 2026, with management describing the latter as 41% year-over-year growth. Revenue is not ARR, and the quarterly result should not be annualized into a run-rate without seasonality evidence. At December 31, 2025, the company reported more than 600,000 assessed patients, 219,000 patients assessed during 2025, more than 1,465 U.S. accounts, and 843 full-time employees globally. Its undated About page now claims more than 750,000 patients treated and more than 1,800 institutions using Heartflow. Those later website measures indicate expansion, but "accounts" and "institutions" are not documented as identical denominators and should not be presented as a calculated growth rate.[CO005, CO006, CO007, CO008, CO009]

1.3 Leadership, Governance, and Capital Formation

Public disclosures identify John Farquhar as president, chief executive officer, and director; Vikram Verghese as chief financial officer; and William Weldon as board chair. The official biographies add relevant medtech and public-company experience, while the filing warns that Heartflow carries no key-person insurance for executives or other employees. The company completed its IPO in August 2025 and reported approximately $332.4 million of net proceeds in the annual filing, using 2025 financing proceeds in part to repay $115.1 million of term-loan principal. The assigned Forge page is not reliable enough to establish a single cumulative funding total: its narrative says $890.7 million across 12 rounds, while its structured snapshot says $755.52 million.[CO010, CO011, CO012, CO013]

1.4 Milestones and Open Risks

Heartflow's sequence from 2007 incorporation to 2015 commercialization and a 2025 public listing is supported by filings, but its current risk profile cannot be reduced to the growth milestones. In October 2025, Heartflow and certain employees received civil investigative demands from the U.S. Department of Justice concerning provider financial and contractual arrangements and sales and marketing activity under the Anti-Kickback Statute and False Claims Act. The 10-K states that duration, outcome, and possible financial impact could not yet be estimated. An independent but explicitly AI-generated Seeking Alpha item separately identifies clinician adoption, outcomes evidence, physician education, and back-half revenue weighting as Plaque risks; it is a weak secondary signal, not independent verification. Barchart's price-indicator methodology is likewise market timing evidence, not operating diligence.[CO014, CO015, CO016]

1.5 Exhibits

2.1 Market boundary and substitutes

The investable market is the software-enabled analysis attached to coronary computed tomography angiography (CCTA) for symptomatic coronary artery disease, not all cardiac imaging, CAD treatment, or CT equipment. Heartflow's current paid products add physiology and plaque characterization to a CCTA that a provider has already performed; RoadMap and PCI Navigator are described as integrated workflow features rather than stand-alone products. The clinically relevant status quo therefore includes stress SPECT, stress echocardiography, PET, review of CCTA alone, and invasive angiography or invasive FFR. CCTA's guideline position is a demand driver, but Heartflow remains downstream of the decision to order a suitable scan. Asymptomatic risk prediction is an adjacency, not present serviceable demand, because the company says additional evidence, regulatory approval, payer coverage, and commercialization work are still required.[CM001, CM002, CM013, CM014]

2.2 Sizing through patient, product, and realized-demand lenses

Heartflow estimates an approximately $5 billion current U.S. opportunity for FFRCT and Plaque Analysis. Its disclosed construction starts with an estimated 9.5 million unique stable chest-pain patients receiving non-invasive tests annually, then applies clinical-eligibility assumptions and assumed selling prices. That produces approximately 3.1 million FFRCT-eligible patients and $3.3 billion at a $1,067 average sales price, plus approximately 5.5 million plaque-eligible patients and an incremental $1.7 billion at $300. These are overlapping product opportunities from the same pathway, not independent populations or a conversion funnel. The best public adoption cross-check is also company-issued: 195,000 U.S. patients analyzed in 2025 represented less than 2% of the company's overall opportunity and about 19% of current U.S. CCTA volume. Neither retained independent source reconstructs the denominator, eligibility filters, realized net price, or CAGR.[CM003, CM004, CM005, CM006, CM007, CM008]

2.3 Buyer, user, payer, and adoption path

Adoption is a multi-stakeholder enterprise motion. Imaging physicians and radiologists influence account activation and scan interpretation; referring cardiologists drive case volume; interventional cardiologists consume planning information; health systems or imaging facilities contract for the service; and government and commercial payers determine whether the economics support routine use. Heartflow primarily charges a usage fee when a physician orders and receives FFRCT Analysis, Plaque Analysis, or both, so an installed account is not equivalent to recurring utilization. The company says a new account generally takes 12 months to approach steady state, defined as FFRCT use on roughly 33% of account CCTAs. Its year-end 2025 filing reported more than 1,465 U.S. accounts, while the current homepage reports more than 1,800 institutions; the differing labels, dates, and geography prevent treating those figures as a clean growth series.[CM009, CM010, CM011, CM012, CM013, CM014, CM015]

2.4 Drivers, constraints, and valuation relevance

The strongest demand drivers are guideline support for CCTA, broad FFRCT coverage, new Plaque Analysis coding and coverage, no required capital-equipment purchase, and the ability to sell more than one analysis from the same scan. The first-quarter 2026 result supplies a realized-demand signal: company-issued results reported $52.6 million of revenue, up 41% year over year, primarily from higher U.S. FFRCT volume. The principal constraints are equally structural. Heartflow depends on local CCTA capacity and image quality, physician behavior change, multi-party workflow integration, and coverage and payment decisions outside its control. FFRCT coverage was reported at about 99% of U.S. covered lives, whereas Plaque Analysis coverage was about 75%, leaving the newer product more exposed to payer conversion. For valuation, a large company TAM should therefore be discounted until utilization cohorts, realized price by site type, payer mix, and independently reproducible serviceable-market evidence are available.[CM002, CM011, CM012, CM013, CM015, CM016]

2.5 Exhibits

3.1 Competitive Landscape & Market Structure

Heartflow operates in a multi-tiered competitive arena defined by distinct technological approaches to diagnosing coronary artery disease. Heartflow's core commercial platform transforms standard coronary computed tomography angiography (CCTA) scans via artificial intelligence algorithms into non-invasive anatomical and physiological diagnostic models, specifically Heartflow FFRCT Analysis and Heartflow Plaque Analysis. In doing so, Heartflow faces primary competition from traditional non-invasive functional tests, direct competition from specialized venture-backed AI software developers, and long-term platform risk from global medical imaging equipment conglomerates. Traditional non-invasive diagnostic modalities—including single-photon emission computed tomography (SPECT), stress echocardiography, positron emission tomography (PET), and invasive diagnostic catheterization—represent the entrenched standard of care across hospital cardiology departments. Major multi-national commercial organizations including Siemens Healthineers AG, GE Healthcare, and Koninklijke Philips N.V. manufacture the imaging hardware for these traditional modalities as well as the CT scanners required to acquire CCTA scans. Consequently, these imaging giants maintain dual positioning as essential upstream data suppliers and formidable potential software competitors who could bundle native analysis tools into their scanner hardware ecosystems.[CP001, CP002, CP003, CP004]

3.2 Direct AI Coronary Challengers & Feature Differentiation

Direct competition within the specialized CCTA-based AI software category includes agile, venture-backed innovators such as Cleerly, Inc., Elucid Bioimaging Inc., and Keya Medical Technology Co., Ltd. These specialized peers focus on algorithmic characterization, vascular biology, and plaque quantification. In particular, Cleerly emphasizes total plaque volume and phenotypic characterization rather than hemodynamic flow reserve alone. Heartflow's regulatory disclosures explicitly highlight that several agile competitors commercially launched plaque analysis software ahead of Heartflow Plaque Analysis, potentially establishing first-mover relationships and creating price competition for hospital software budgets. Heartflow has countered this competitive pressure by building an integrated diagnostic suite that pairs anatomical Roadmap Analysis and physiological FFRCT with comprehensive Plaque Analysis and pre-procedural catheterization planning via PCI Navigator, supported by extensive clinical validation spanning over 625 peer-reviewed publications and a proprietary training database of over 200 million annotated CT images.[CP005, CP006, CP007, CP008, CP009]

3.3 Moat Durability, Switching Costs, and Regulatory Headwinds

Heartflow's competitive moat rests on four pillars: an extensive proprietary clinical trial evidence base, deep enterprise workflow integration into PACS and electronic health record systems, dedicated CPT reimbursement coding, and dedicated customer success field teams supporting hospital clinical and operational teams. However, Heartflow's business model remains sensitive to external capital and payer reimbursement structures. Unlike diversified multi-national conglomerates that generate billions across hardware, devices, and pharmaceuticals, Heartflow depends heavily on reimbursement rates established by third-party payors and Medicare. In its regulatory filings, Heartflow noted that the Centers for Medicare & Medicaid Services (CMS) proposed 2026 OPPS rule could reduce the Medicare reimbursement rate for the clinical Ambulatory Payment Classification (APC) that includes Heartflow FFRCT Analysis by up to 15%. This regulatory reimbursement volatility highlights that software-only diagnostic providers face continuous price realization pressure that capital-equipment incumbents can more easily absorb across diversified revenue lines.[CP010, CP011, CP012, CP013, CP014]

3.4 Exhibits

4.1 Revenue Streams and Pricing Architecture

Heartflow operates a dual-modality commercial model for coronary computed tomography angiography (CCTA) post-processing, consisting of its established Heartflow FFRCT Analysis and the emerging Heartflow Plaque Analysis. In the second quarter of FY2026, Heartflow generated $64.1 million in total revenue, reflecting 48% year-over-year expansion [CI001]. Growth was heavily led by the domestic market, where U.S. revenue expanded 51% year-over-year to $59.6 million, while international and other revenue accounted for $4.5 million [CI001]. Flagship FFRCT processing remains the company's primary economic engine, benefiting from nationwide clinical adoption and Category I CPT reimbursement coverage across 99.5% of insured U.S. commercial and Medicare lives [CI008]. Meanwhile, Plaque Analysis represents Heartflow's primary growth vector, contributing $7.8 million in quarterly revenue during Q2 FY2026 [CI001]. Management raised full-year 2026 plaque revenue expectations to a range of $29 million to $31 million, projecting roughly 1,250 activated plaque hospital accounts by year-end [CI002]. Hospital outpatient reimbursement under Medicare APC schedules provides a predictable fee structure, but health systems contract privately under list and enterprise volume tiers, creating opacity in realized per-case pricing [CI008].

4.2 Cost Structure, Unit Economics, and Margin Expansion

Heartflow's operating model exhibits substantial gross margin expansion alongside high commercial fixed costs. Non-GAAP gross margin expanded 770 basis points year-over-year to 83.3% in Q2 FY2026, compared to 75.6% in Q2 FY2025 [CI004]. Full-year non-GAAP gross margin guidance was subsequently raised to approximately 82%, with executive management targeting an 85% mid-term gross margin run-rate underpinned by algorithmic automation and volume leverage [CI004]. Total global revenue cases reached 84,491 in Q2 FY2026, an increase of 74% year-over-year that illustrates strong procedure demand [CI001]. The delivery cost structure primarily comprises cloud computational infrastructure on Amazon Web Services and specialized human-in-the-loop image quality analysts who inspect anatomical vessel segmentations prior to clinical delivery. Despite gross profit expansion, operational overhead remains heavy: Q2 FY2026 selling, general, and administrative expenses reached $37.8 million, while research and development investment totaled $23.5 million [CI005]. Heartflow reported a non-GAAP operating loss of $7.9 million for the quarter, an improvement from an $11.5 million operating loss in the prior-year period [CI005]. Critical unit-level disclosures—including customer acquisition cost, payback periods, and net revenue retention by hospital cohort—remain private and undisclosed [CI013].

4.3 Capital Adequacy, Cash Burn, and Contingent Liabilities

As of June 30, 2026, Heartflow held $246.8 million in cash, cash equivalents, and investments on its balance sheet [CI006]. Operating cash burn has decelerated from historical levels: net cash used in operating activities stood at $54.0 million for full-year 2025, down from $69.0 million in 2024 and $76.4 million in 2023 [CI007]. Management maintains that existing liquid resources provide sufficient runway to achieve self-sustaining operating profitability without requiring dilutive equity financing [CI006]. Forge's historical financing page reports inconsistent cumulative funding totals of $890.7 million and $755.52 million, so neither figure is treated as current liquidity [CI014]. However, the business faces material ongoing legal and regulatory overhangs. In October 2025, the U.S. Department of Justice served Heartflow and certain employees with Civil Investigative Demands under the federal Anti-Kickback Statute and False Claims Act regarding financial arrangements with healthcare providers and marketing practices [CI011]. Concurrently, Heartflow is engaged in multi-year intellectual property litigation against competitor Cleerly, leading management to adjust non-GAAP SG&A metrics to exclude patent litigation costs [CI012]. While consensus Wall Street analyst estimates anticipated a Q2 FY2026 loss of approximately $-0.22 per share [CI009], the stock traded at $49.32 as of early October 2026, implying an equity market valuation of approximately $4.29 billion across 86.95 million shares outstanding [CI003, CI010].

4.4 Exhibits

5.1 Product Portfolio Across the Non-Invasive CCTA Care Pathway

Heartflow has commercialized an integrated, cloud-delivered software platform designed to transform coronary artery disease (CAD) diagnosis and treatment management. Rather than relying on traditional stress-based non-invasive tests (NITs) such as SPECT, stress echocardiography, or treadmill tests—which suffer from significant false-positive and false-negative rates—the Heartflow Platform utilizes a single standard coronary computed tomography angiography (CCTA) dataset to generate a personalized three-dimensional anatomical and physiological digital twin of the patient's coronary arteries. The clinical suite comprises three commercially cleared software applications alongside an upcoming interventional planning solution. Heartflow RoadMap Analysis automatically extracts coronary anatomy from acceptable CCTA scans to highlight clinically relevant areas of luminal narrowing, functioning as a diagnostic workflow acceleration tool. Heartflow FFRCT Analysis, cleared via FDA de novo 510(k) in 2014, applies computational fluid dynamics (CFD) under simulated maximal hyperemia to calculate fractional flow reserve values along every major branch of the coronary arterial tree, using 0.80 as the validated threshold for hemodynamically significant stenosis. Heartflow Plaque Analysis, introduced to limited commercial education in late 2023, quantifies total plaque volume and characterizes non-calcified versus calcified components to guide long-term preventive medical therapy. A fourth application, Heartflow PCI Planner, is scheduled for commercial release in 2026 to assist interventional cardiologists with virtual stent placement and procedural modeling. [CE001, CE002, CE003, CE004, CE005]

5.2 Operating Model, Algorithm Pipeline, and Production Infrastructure

Heartflow operates a centralized software-as-a-service processing pipeline hosted on Amazon Web Services (AWS) cloud infrastructure. Medical centers securely upload DICOM image series acquired from outpatient or hospital CT scanners via Heartflow's lightweight gateway client directly into the cloud. The processing workflow initiates with deep convolutional neural network models trained on an annotated corpus exceeding 160 million CCTA images, segmenting the lumen boundaries, coronary vessel centerlines, and myocardial volume. Because biological image artifacts such as motion blur, high heart rates, and heavy calcification can distort algorithmic segmentation, Heartflow employs a human-in-the-loop quality control architecture. Specialized production analysts inspect algorithmically extracted models through proprietary review software, manually editing and approving coronary segmentations before high-performance computational simulations execute. The simulation engine resolves Navier-Stokes blood flow equations across patient-specific boundary conditions, deriving physiological pressures without requiring pharmacologic adenosine administration. Finished reports are returned to the ordering physician within hours through an interactive web portal, downloadable PDF summaries, and direct electronic health record (EHR) and PACS integrations. [CE006, CE007, CE008, CE009]

5.3 Clinical Validation, Intellectual Property Moat, and Enterprise Security

Heartflow's clinical differentiation is anchored by extensive prospective randomized controlled trials and clinical registries. The pivotal NXT trial established an 86% per-vessel diagnostic accuracy for FFRCT relative to invasive catheter-based FFR measurements, compared to 65% for CCTA alone (p < 0.001). The prospective PRECISE trial demonstrated that a CCTA plus Heartflow FFRCT diagnostic pathway resulted in a 69% reduction in diagnostic-only invasive coronary angiograms (ICA) while doubling the yield of catheterizations that proceeded to therapeutic revascularization from 30.5% to 71.9%. The company protects its technological foundation through an extensive global intellectual property estate comprising approximately 617 issued patents and 93 pending applications globally as of December 31, 2025. This portfolio covers computer-implemented CFD simulations, machine-learning-driven anatomical boundary extraction, interactive 3D graphical interfaces, and alternative machine-learning-only FFR estimation methods, with key US patents expiring through 2044. Enterprise healthcare trust is supported by an Information Security Management System holding HITRUST, ISO 27001, ISO 13485, SOC 2 Type 2, and UK CyberEssentials certifications, providing formal compliance for protected health information handling. [CE010, CE011, CE012, CE013, CE014, CE015]

5.4 Exhibits

6.1 Buyer, user, payer, and beneficiary map

Heartflow sells the platform to medical providers rather than directly to patients. Its filing defines an account as an individual facility ordering FFRCT Analysis, Plaque Analysis, or both, while a customer may be either one account or a health or hospital system containing several accounts. Physicians are the ordering users, and the account is billed when an analysis is delivered. Government and commercial payers influence realized economics through reimbursement and volume rebates, but they are not described as the contracting customer. Patients are the clinical beneficiaries and cumulative case population. Research programs such as PREEMPT may validate use, but they should not be counted as commercial customers without procurement evidence.[CU001, CU002, CU003, CU011]

6.2 Adoption trajectory without false comparability

The public adoption record is substantial but mixes different units. Heartflow reported more than 1,465 U.S. accounts as of December 31, 2025; an April 2026 complaint described relationships with more than 1,400 U.S. hospitals including 80% of the top 50 heart hospitals; and a July 2026 company release said adoption exceeded 1,800 institutions globally. Patient figures also moved from more than 650,000 in that July release to more than 750,000 in a September company job posting and the current homepage. These observations are not a same-population funnel: account, hospital, institution, and cumulative patient denominators differ, and company-issued figures are not independent customer confirmation. Quarterly revenue is therefore shown only as a commercial momentum indicator, not as a customer-count substitute.[CU001, CU006, CU007, CU008, CU009, CU012, CU013]

6.3 Usage expansion is visible; retention is not

Heartflow's commercial model can expand inside an installed account as referring physicians order more analyses and as Plaque is activated alongside FFRCT. TradingKey reported that the 340 accounts added in 2025 were ramping in line with management expectations, while new FFRCT accounts generally require about one year to approach mature utilization. The same report said Plaque remains below management's roughly 60% eligible-CCTA ceiling even as the year-end 2026 activation target increased to approximately 1,250 accounts. This is credible evidence of an expansion mechanism, not proof of retention: substantially all revenue was usage-driven, customer contracts were generally cancellable on 30 days' notice, and public NRR, GRR, churn, renewal, and cohort-level utilization data remain unavailable.[CU003, CU014, CU015, CU016]

6.4 Named proof and concentration remain the diligence bottlenecks

The assigned pool contains aggregate scale, clinical investigators, and research relationships, but no named paying hospital whose production deployment, contract status, utilization, and outcome are all public. A University of Kentucky HealthCare investigator is quoted about DECIDE, yet the release does not call the institution a Heartflow customer. PREEMPT establishes a research provider role, not hospital procurement. Concentration disclosure is similarly incomplete: Heartflow reported that no customer contributed 10% or more of revenue in 2023-2025, but warned that centralized decisions across multi-account health systems could cause disproportionate account loss. The sub-10% threshold therefore limits single-customer revenue concentration without resolving network-level procurement exposure.[CU004, CU005, CU010, CU011]

6.5 Exhibits

7.1 Legal, regulatory, and reimbursement exposure

The most immediate disclosed legal risk is active rather than hypothetical: Heartflow reported that it and certain employees received U.S. Department of Justice civil investigative demands in October 2025 concerning provider financial and contractual arrangements and sales and marketing activities under the Anti-Kickback Statute and False Claims Act. The company was cooperating but could not estimate duration or outcome, and said the result could materially affect the business, financial condition, results, or cash flows. Separately, Medicare and commercial payment remain recurring model dependencies. The 2025 Form 10-K explained that CMS resets rates using hospital cost and charge data and cited a July 2025 proposal for an up-to-15% reduction as a historical example; the fetched evidence does not establish that proposal's final outcome. A final enforcement action, exclusion risk, material repayment, or reimbursement reset that materially impairs account economics would be a thesis-break event.[CR001, CR002, CR003, CR004]

7.2 Clinical input and execution quality

Heartflow's output depends on a chain that begins outside its own software. Independent SCCT guidance states that coronary CTA diagnostic quality depends on hardware, software, and acquisition protocols, while Heartflow's filing says inbound image limitations can affect its analyses. The same filing warns that AI models, analyst review, and software can contain undetected errors; it also discloses past code and release-process defects that intermittently interrupted physician use, with a subset reported through FDA MAUDE. These are not proof of current systematic inaccuracy, but they make image-acceptance rates, corrected-report rates, MAUDE trends, turnaround-time misses, and complaint closure times essential monitoring indicators. A sustained increase in clinically significant corrections or a recall would challenge confidence in the platform's risk-adjusted adoption case.[CR005, CR006, CR013, CR014]

7.3 Infrastructure, security, and counterparty concentration

Heartflow outsources all cloud infrastructure to AWS. Its filing says outages could make the clinical service inaccessible and that AWS can terminate on 30 days' notice, or sooner under specified conditions; the filing does not disclose an active multi-cloud failover. The platform also stores and transmits customer and patient identifying information, so a breach could combine downtime, liability, lost certifications, customer loss, and remediation expense. Customer concentration is subtler: no customer represented 10% or more of 2025 revenue, yet decision-making for multiple accounts can sit with a relatively small number of health systems. Company-issued hiring material shows that complaint investigation, quality and accuracy feedback, service levels, and support scaling require a dedicated cross-functional function. Recovery objectives, failover-test results, security incidents, health-system concentration, and support service-level performance remain non-public diligence items.[CR007, CR008, CR009, CR011, CR013, CR014]

7.4 Financial, governance, and market-risk implications

Product concentration and losses make execution setbacks more consequential. Heartflow FFRCT Analysis represented 98% of 2025 revenue, and the company reported a $116.8 million FY2025 net loss after a $92.4 million net loss for the first nine months; these are accounting losses, not cash burn or runway. The public website claims more than 750,000 patients treated and more than 1,800 institutions using Heartflow but gives no as-of date in the fetched page, so operating scale should not be mistaken for disclosed retention or service reliability. At the IPO, officers, directors, 5% holders, and affiliates were expected to own about 50.1% and exercise significant voting control; that is an IPO-date estimate, not a current ownership measure. MarketBeat reported a 2.73 beta on October 3, 2026, indicating public-market volatility in that data set. Investment monitoring should therefore distinguish accounting loss from cash use and require current ownership, cash-flow, product-mix, reliability, and retention evidence.[CR003, CR010, CR014, CR015, CR016]

7.5 Exhibits

8.1 Recommendation and Entry Discipline

The evidence supports a track/research-more recommendation rather than a price-insensitive buy. Heartflow reported $176.0 million of 2025 revenue, up 40%, followed by $52.6 million of first-quarter 2026 revenue, up 41%, and an 80.2% first-quarter gross margin. These are revenue and gross-margin measures, not ARR or proof of recurring retention. The same first-quarter release reported a $29.5 million net operating loss, including a $7.5 million non-cash impairment; that accounting loss is not cash burn. The 2025 filing separately reported $54.0 million of operating cash use and $280.2 million of year-end cash, equivalents, and investments. Those balances do not establish current cash or runway. Most importantly, no successful allocated source provides an October 2026 share price, net debt bridge, enterprise value, or transaction-ready entry multiple. Without those inputs, neither a target return nor a valuation range is supportable.[CV001, CV002, CV003, CV004, CV005, CV006, CV007, CV016]

8.2 Thesis, Financing Context, and Downside

The thesis combines rapid case-driven revenue growth, high gross margin, and public-market access. Heartflow's August 2025 IPO sold 19,166,667 shares at $19.00 and generated about $332.4 million of net proceeds. At closing, $98.3 million of convertible notes converted into 6,470,743 common shares at $15.20, a 20% discount to the IPO price. That conversion is a historical dilution fact, not evidence of a continuing liquidation preference. Financing-history providers also conflict: Tracxn reports $936 million over 12 rounds, while Forge reports $890.7 million over 12 rounds and a $546.5 million April 2023 private post-money valuation. None is a current public valuation. The anti-thesis is operational concentration: FFRCT represented 98% of 2025 revenue. No individual customer contributed 10% or more, but Heartflow warned that decision-making across accounts can still be concentrated. Its April 2026 patent complaint against Cleerly adds a live legal and competitive dependency whose outcome is not established by the complaint.[CV008, CV009, CV010, CV011, CV012, CV013, CV014, CV015]

8.3 Scenarios, Exit Readiness, and Final Diligence

The bull signal is execution against management's $228 million to $232 million 2026 revenue guidance while preserving roughly 80% gross margin and reducing operating cash use; even then, upside cannot be quantified without a current enterprise value. The base case is continued growth with persistent losses and FFRCT concentration, which supports monitoring rather than underwriting a precise return. The bear case is slower growth, gross-margin compression, rising operating cash use, failed product diversification, or an adverse litigation development. Heartflow is already publicly listed, so the relevant exit question is price and liquidity rather than IPO readiness. Final diligence should obtain current fully diluted shares, cash, investments, debt, share price, product-level revenue, retention, reimbursement realization, and peer transaction multiples on a common period and denominator. Thesis-break triggers are a material deceleration from disclosed growth, sustained margin deterioration, worsening cash use, continued near-total FFRCT dependence, or legal outcomes that impair commercialization. Until those checks are complete, scenario probabilities and dollar valuation ranges remain gaps rather than investable estimates.[CV002, CV003, CV005, CV007, CV010, CV015, CV016]

8.4 Exhibits